- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- PhRMA report lists 271 vaccines in development
- ROUNDTABLE: Pharmacy’s future in sync with technology
TARRYTOWN, N.Y. — The Food and Drug Administration has approved a drug for treating a complication of a disease that results from vein blockages in the eye.
Regeneron Pharmaceuticals announced the approval of Eylea (aflibercept) for treating macular edema following central retinal vein occlusion, or CRVO. Eylea already was approved for treating neovascular age-related macular degeneration, another eye disease.
"This second U.S. approval for Eylea provides physicians and patients with a new treatment option for the treatment of macular edema following CRVO," Regeneron chief scientific officer and Regeneron Labs president George Yancopoulos said.